2658-6533Research Results in Biomedicine2658-653310.18413/2658-6533-2025-11-4-0-33938Genetics<strong>The relationship between the genetic determinants of SHBG and the hormonal profile of patients with uterine fibroids</strong><br /> &nbsp;<strong>The relationship between the genetic determinants of SHBG and the hormonal profile of patients with uterine fibroids</strong><br /> &nbsp;PonomarenkoMarina S.PonomarenkoMarina S.ponomarenkomc@yandex.ru202511400

Background: Uterine fibroids are benign hormone-dependent tumors that affect the muscle layer of the uterus and are common in women of reproductive age. Genetic factors are important in the development of this neoplasm. Candidate genes associated with the level of sex hormone binding globulin (SHBG) may be involved in the pathogenetics of uterine fibroids. The aim of the study: To evaluate the relationship between polymorphic gene variants associated with SHBG levels and the hormonal status of patients with uterine fibroids. Materials and methods: The hormonal profile of the 83 patients with uterine fibroids included in the study group was examined. This included the measurement of serum concentrations of follicle-stimulating hormone (FSH), luteinising hormone (LH), oestradiol, testosterone, prolactin and progesterone. Genotyping of nine single nucleotide polymorphisms (SNPs) associated with sex hormone-binding globulin (SHBG) levels was also performed. The gPLINK software was used to search for associations of SNPs associated with the level of SHBG with the level of sex hormones in patients with uterine fibroids (linear regression method). 4 genetic models (allelic/additive/dominant/recessive) were tested; transformed values of the concentrations of sex hormones in the blood serum were included in the calculations. Results: Three molecular genetic markers are associated with estradiol levels: rs3779195 BAIAP2L1 [T/A] (7chr.) (pperm=0.020 &ndash; 0.048; &beta;=-0.372 &ndash; -0.394), rs7910927 JMJD1C [G/T] (10chr.) (pperm=0.027 &ndash; 0.048; &beta;=-0.228 &ndash; -0.379), rs10454142 PPP1R21 [T/C] (2chr.) (pperm=0.050; &beta;=0.318), luteinizing hormone &ndash; rs4149056 SLCO1B1 [T/C] (12chr.) (pperm=0.043 &ndash; 0.048; &beta;=0.361 &ndash; 0.369), and with a prolactin concentration (pperm=0.021; &beta;=0.968), progesterone (pperm=0.050; &beta;=-1.276,) and testosterone (pperm=0.050; &beta;=-0.744) in the blood serum of patients with uterine fibroids, the polymorphic locus rs8023580 NR2F2 [T/C] (15chr.) is associated. Conclusion: The involvement of SHBG candidate genes in the hormonal profile of patients with uterine fibroids was established.

Background: Uterine fibroids are benign hormone-dependent tumors that affect the muscle layer of the uterus and are common in women of reproductive age. Genetic factors are important in the development of this neoplasm. Candidate genes associated with the level of sex hormone binding globulin (SHBG) may be involved in the pathogenetics of uterine fibroids. The aim of the study: To evaluate the relationship between polymorphic gene variants associated with SHBG levels and the hormonal status of patients with uterine fibroids. Materials and methods: The hormonal profile of the 83 patients with uterine fibroids included in the study group was examined. This included the measurement of serum concentrations of follicle-stimulating hormone (FSH), luteinising hormone (LH), oestradiol, testosterone, prolactin and progesterone. Genotyping of nine single nucleotide polymorphisms (SNPs) associated with sex hormone-binding globulin (SHBG) levels was also performed. The gPLINK software was used to search for associations of SNPs associated with the level of SHBG with the level of sex hormones in patients with uterine fibroids (linear regression method). 4 genetic models (allelic/additive/dominant/recessive) were tested; transformed values of the concentrations of sex hormones in the blood serum were included in the calculations. Results: Three molecular genetic markers are associated with estradiol levels: rs3779195 BAIAP2L1 [T/A] (7chr.) (pperm=0.020 &ndash; 0.048; &beta;=-0.372 &ndash; -0.394), rs7910927 JMJD1C [G/T] (10chr.) (pperm=0.027 &ndash; 0.048; &beta;=-0.228 &ndash; -0.379), rs10454142 PPP1R21 [T/C] (2chr.) (pperm=0.050; &beta;=0.318), luteinizing hormone &ndash; rs4149056 SLCO1B1 [T/C] (12chr.) (pperm=0.043 &ndash; 0.048; &beta;=0.361 &ndash; 0.369), and with a prolactin concentration (pperm=0.021; &beta;=0.968), progesterone (pperm=0.050; &beta;=-1.276,) and testosterone (pperm=0.050; &beta;=-0.744) in the blood serum of patients with uterine fibroids, the polymorphic locus rs8023580 NR2F2 [T/C] (15chr.) is associated. Conclusion: The involvement of SHBG candidate genes in the hormonal profile of patients with uterine fibroids was established.

uterine fibroidspolymorphismsex hormone binding globulinuterine fibroidspolymorphismsex hormone binding globulinСписок литературыBulun SE, Yin P, Wei J, et al. Uterine fibroids. Physiological Reviews. 2025;105(4):1947-1988. DOI: https://doi.org/10.1152/physrev.00010.2024Yang Q, Ciebiera M, Bariani MV, et al. Comprehensive Review of Uterine Fibroids: Developmental Origin, Pathogenesis, and Treatment. Endocrine Reviews.&nbsp;2022;43(4):678-719. DOI: https://dx.doi.org/10.1210/endrev/bnab039Zhang Z, Huang H, Jiang K, et al. Global, regional and national uterine fibroid burdens from 1990 to 2021 and projections until 2050: results from the GBD study. BMC Women&#39;s Health. 2025;25(1):423. DOI: https://doi.org/10.1186/s12905-025-03974-yHarrington A, Bonine NG, Banks E, et al. Direct Costs Incurred Among Women Undergoing Surgical Procedures to Treat Uterine Fibroids. Journal of Managed Care and Specialty Pharmacy. 2020;26(1-a):S2-S10. DOI: https://doi.org/10.18553/jmcp.2020.26.1-a.s2Li B, Wang F, Chen L, et al. Global epidemiological characteristics of uterine fibroids. Archives of Medical Science. 2023;19(6):1802-1810. DOI: https://doi.org/10.5114/aoms/171786Kim J, Williams A, Noh H, et al. Genome-wide meta-analysis identifies novel risk loci for uterine fibroids within and across multiple ancestry groups. Nature Communications. 2025;16(1):2273. DOI: https://doi.org/10.1038/s41467-025-57483-5Ponomarenko MS, Reshetnikov EA, Ponomarenko IV, et al. Molecular genetic factors of uterine fibroids formation. Medical Council. 2025;4:21-25. Russian. DOI: https://doi.org/10.21518/ms2025-051Alsudairi HN, Alrasheed AT, Dvornyk V. Estrogens and uterine fibroids: an integrated view. Research Results in Biomedicine. 2021;7(2):156-163. DOI: https://dx.doi.org/10.18413/2658-6533-2021-7-2-0-6Ponomarenko IV, Polonikov AV, Churnosov MI. Polymorphic loci of the LHCGR gene associated with the development of uterine fibroids. Obstetrics and Gynecology. 2018;10:86-91. Russian. DOI: https://dx.doi.org/10.18565/aig.2018.10.86-91Ponomarenko I, Reshetnikov E, Polonikov A, et al. Candidate Genes for Age at Menarche Are Associated With Uterine Leiomyoma. Frontiers in Genetics. 2021;11:512940. DOI: https://doi.org/10.3389/fgene.2020.512940Ponomarenko IV, Churnosov MI. Contemporary ideas about etiopathogenesis and risk factors of uterine leiomyoma. Obstetrics and Gynecology. 2018;8:27-32. Russian. DOI: https://dx.doi.org/10.18565/aig.2018.8.27-32Ponomarenko MS, Reshetnikov EA, Ponomarenko IV, et al. Etiopathogenetic mechanisms of uterine fibroids development. Obstetrics and Gynecology. 2024;1:34-41. Russian. DOI: https://dx.doi.org/10.18565/aig.2023.241Lv M, Yu J, Huang Y, et al. Androgen Signaling in Uterine Diseases: New Insights and New Targets. Biomolecules. 2022;12(11):1624. DOI: https://doi.org/10.3390/biom12111624Ploumaki I, Macri VI, Segars JH, et al. Progesterone signaling in uterine fibroids: Molecular mechanisms and therapeutic opportunities. Life Sciences. 2025;362:123345. DOI: https://doi.org/10.1016/j.lfs.2024.123345Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for wholegenome association and population-based linkage analyses. American Journal of Human Genetics. 2007;81(3):559-575. DOI: https://dx.doi.org/10.1086/519795Che R, Jack JR, Motsinger-Reif AA, et al. An adaptive permutation approach for genome-wide association study: evaluation and recommendations for use. BioData Mining. 2014;7:9. DOI: https://doi.org/10.1186/1756-0381-7-9Borahay MA, Al-Hendy A, Kilic GS, et al. Signaling Pathways in Leiomyoma: Understanding Pathobiology and Implications for Therapy. Molecular Medicine. 2015;21(1):242-256. DOI: https://doi.org/10.2119/molmed.2014.00053Machado-Lopez A, Sim&oacute;n C, Mas A. Molecular and Cellular Insights into the Development of Uterine Fibroids. International Journal of Molecular Sciences. 2021;22(16):8483. DOI: https://dx.doi.org/10.3390/ijms22168483Ali M, Ciebiera M, Vafaei S, et al. Progesterone Signaling and Uterine Fibroid Pathogenesis; Molecular Mechanisms and Potential Therapeutics. Cells. 2023;12(8):1117. DOI: https://doi.org/10.3390/cells12081117Szucio W, Bernaczyk P, Ponikwicka-Tyszko D, et al. Progesterone signaling in uterine leiomyoma biology: Implications for potential targeted therapy. Advances in Medical Sciences. 2024;69(1):21-28. DOI: https://doi.org/10.1016/j.advms.2024.01.001Omar M, Laknaur A, Al-Hendy A, et al. Myometrial progesterone hyper-responsiveness associated with increased risk of human uterine fibroids. BMC Women&#39;s Health. 2019;19(1):92. DOI: https://doi.org/10.1186/s12905-019-0795-1G&oacute;rski K, Zgliczyński S, Stelmachowska-Banaś M, et al. Uterine fibroids in women diagnosed with acromegaly: a systematic review. Reviews in Endocrine and Metabolic Disorders. 2024;25(4):773-781. DOI: https://doi.org/10.1007/s11154-024-09883-zIslam MS. Advances in uterine fibroid research: linking progesterone and the transforming growth factor-&beta; signaling pathway. Fertility and Sterility. 2024;122(2):272-273. DOI: https://doi.org/10.1016/j.fertnstert.2024.05.004Bariani MV, Cui YH, Ali M, et al. TGF&beta; signaling links early life endocrine-disrupting chemicals exposure to suppression of nucleotide excision repair in rat myometrial stem cells. Cellular and Molecular Life Sciences. 2023;80(10):288. DOI: https://doi.org/10.1007/s00018-023-04928-zSimon JA, Catherino W, Segars JH, et al. Ulipristal acetate for treatment of symptomatic uterine leiomyomas: a randomized controlled trial. Obstetrics and Gynecology. 2018;131(3):431-439. DOI: https://doi.org/10.1097/AOG.0000000000002462Milewska G, Ponikwicka-Tyszko D, Bernaczyk P, et al. Functional evidence for two distinct mechanisms of action of progesterone and selective progesterone receptor modulator on uterine leiomyomas. Fertility and Sterility. 2024;122(2):341-351. DOI: https://doi.org/10.1016/j.fertnstert.2024.02.046Lewis TD, Malik M, Britten J, et al. Ulipristal acetate decreases active TGF-&beta;3 and its canonical signaling in uterine leiomyoma via two novel mechanisms. Fertility and Sterility. 2019;111(4):683-684. DOI: https://doi.org/10.1016/j.fertnstert.2018.12.026Ciebiera M, Włodarczyk M, Wrzosek M, et al. Ulipristal acetate decreases transforming growth factor &beta;3 serum and tumor tissue concentrations in patients with uterine fibroids. Fertility and Sterility. 2018;109(3):501-507. DOI: https://doi.org/10.1016/j.fertnstert.2017.11.023Sinnott-Armstrong N, Naqvi S, Rivas M, et al. GWAS of three molecular traits highlights core genes and pathways alongside a highly polygenic background. eLife. 2021;10:e58615. DOI: https://doi.org/10.7554/eLife.58615Ruth KS, Campbell PJ, Chew S, et al. Genome-wide association study with 1000 genomes imputation identifies signals for nine sex hormone-related phenotypes. European Journal of Human Genetics. 2016;24:284-290. DOI: https://doi.org/10.1038/ejhg.2015.102Ponomarenko M, Reshetnikov E, Churnosova M, et al. Obesity/Overweight as a Meaningful Modifier of Associations Between Gene Polymorphisms Affecting the Sex Hormone-Binding Globulin Content and Uterine Myoma. Life. 2025;15(9):1459. DOI: https://doi.org/10.3390/life15091459Ponomarenko M, Reshetnikov E, Churnosova M, et al. Genetic Variants Linked with the Concentration of Sex Hormone-Binding Globulin Correlate with Uterine Fibroid Risk. Life. 2025;15(7):1150. DOI: https://doi.org/10.3390/life15071150Mozzachio K, Moore AB, Kissling GE, et al. Immunoexpression of Steroid Hormone Receptors and Proliferation Markers in Uterine Leiomyoma and Normal Myometrial Tissues from the Miniature Pig, Sus scrofa. Toxicologic Pathology. 2016;44(3):450-457. DOI: https://doi.org/10.1177/0192623315621414Khan KN, Fujishita A, Koshiba A, et al. Expression profiles of E/P receptors and fibrosis in GnRHa-treated and -untreated women with different uterine leiomyomas. PLoS ONE. 2020;15(11):e0242246. DOI: https://doi.org/10.1371/journal.pone.0242246Ali M, Al-Hendy A. Selective progesterone receptor modulators for fertility preservation in women with symptomatic uterine fibroids. Biology of Reproduction. 2017;97(3):337-352. DOI: https://doi.org/10.1093/biolre/iox094Stewart EA, Nowak RA. Uterine Fibroids: Hiding in Plain Sight. Physiology. 2022;37(1):16-27. DOI: https://doi.org/10.1152/physiol.00013.2021Baird DD, Kesner JS, Dunson DB. Luteinizing hormone in premenopausal women may stimulate uterine leiomyomata development. Journal of the Society for Gynecologic Investigation. 2006;13(2):130-135. DOI: https://doi.org/10.1016/j.jsgi.2005.12.001DiMauro A, Sege C, Minor B, et al. Prolactin is Expressed in Uterine Leiomyomas and Promotes Signaling and Fibrosis in Myometrial Cells. Reproductive Sciences. 2022;29(9):2525-2535. DOI: https://doi.org/10.1007/s43032-021-00741-wPasenov KN. Features of associations of SHBG-related genes with breast cancer in women, depending on the presence of hereditary burden and mutations in the BRCA1/CHEK2 genes. Research Results in Biomedicine. 2024;10(1):69-88. Russian. DOI: https://doi.org/10.18413/2658-6533-2024-10-1-0-4Ponomareva TA. Genetic variants of sex hormone-binding globulin and hormonal profile in patients with genital endometriosis. Research Results in Biomedicine. 2025;11(1):75-90. Russian. DOI: https://doi.org/10.18413/2658-6533-2025-11-1-0-4Churnosov VI. Associations of polymorphic loci of candidate genes with the level of sex hormones in patients with endometrial hyperplasia. Research Results in Biomedicine. 2025;11(2):243-262. Russian. DOI: https://doi.org/10.18413/2658-6533-2025-11-2-0-3